Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521212 | 0.83 | PGR (1.00) | PGR | |
| SCHEMBL4103291 | 0.81 | PGR (1.00) | PGR | |
| SCHEMBL3872258 | 0.77 | PGR (1.00) | PGR | |
| SCHEMBL4093836 | 0.76 | PGR (1.00) | PGR | |
| SCHEMBL4099958 | 0.75 | PGR (1.00) | PGR | |
| SCHEMBL7642450 | 0.75 | PGR (0.85) | PGR | |
| SCHEMBL4101423 | 0.74 | PGR (1.00) | PGR | |
| SCHEMBL3874143 | 0.72 | PGR (1.00) | PGR | |
| SCHEMBL6771936 | 0.72 | PGR (0.68) | PGR | |
| SCHEMBL3870526 | 0.72 | PGR (0.73) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | claimed |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | WYETH (US) | 2009-04-16 | — | — | US | claimed |
| US-7115649-B2 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH (US) | 2006-10-03 | — | — | US | claimed |
| EP-1515680-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1531806-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| US-6946454-B2 | Thio-oxindole derivatives | WYETH (US) | 2005-09-20 | — | — | US | claimed |
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | WYETH (US) | 2005-08-04 | — | — | US | claimed |
| EP-1531806-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1515680-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH | 2004-01-08 | — | — | US | claimed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | claimed |
| WO-2004000225-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| WO-2004000227-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| US-6521657-B2 | Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal | WYETH | 2003-02-18 | — | — | US | claimed |
| US-20020169198-A1 | Thio-oxindole derivatives | WYETH (US) | 2002-11-14 | — | — | US | claimed |
| US-20020103248-A1 | Thio-oxindole derivatives | WYETH LLC | 2002-08-01 | — | — | US | claimed |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-8242098-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1181275-A1 | THIO-OXINDOLE DERIVATIVES | American Home Products Corporation (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000066555-A1 | THIO-OXINDOLE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | GPER1, OXTR, SHBG | PGR 44/4885 |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | SRD5A1, SRD5A2, OXER1 | PGR 1297/4885 |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | OXTR, GNRHR, SHBG | PGR 23/4885 |
| US-20020103248-A1 | Thio-oxindole derivatives | PGR, OXTR, PGRMC1 | PGR 1/4885 |
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | PGR, ESR1, PGRMC1 | PGR 1/4885 |
| US-20020169198-A1 | Thio-oxindole derivatives | GPER1, PGR, ESR1 | PGR 2/4885 |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | OXTR, GNRHR, SHBG | PGR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.